Evercore ISI Group Downgrades Tenax Therapeutics to In-Line, Lowers Price Target to $5
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsDowngradesPrice Target
Evercore ISI Group analyst Gavin Clark-Gartner downgrades Tenax Therapeutics (NASDAQ:TENX) from Outperform to In-Line and lowers the price target from $39 to $5.
Evercore ISI Group analyst Gavin Clark-Gartner downgrades Tenax Therapeutics (NASDAQ:TENX) from Outperform to In-Line and lowers the price target from $39 to $5.